Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Recruitment opened Daiichi SankyoPhase 3 NCT07474649
  2. Notable: Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) Recruitment opened Sinovac Biotech Co., LtdPhase 4 NCT07832201
  3. Notable: SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab · Advanced Solid Tumors Recruitment opened Hangzhou Sumgen Biotech Co., Ltd.Phase 1/2 NCT07774611
  4. Notable: K-1728 in Advanced Solid Tumors Recruitment opened KymaThera, Inc.Phase 1/2 NCT07861932
  5. Notable: MK-6916 · Pain After Bunion Removal Surgery (MK-6916-007) Recruitment opened Merck Sharp & Dohme LLCPhase 2 NCT07862595
  6. Notable: Co-administration of GSK3862995B With GSK5784283 · Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Recruitment opened GlaxoSmithKlinePhase 2 NCT07915791
  7. Notable: INCA33890 · Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy Recruitment opened Incyte CorporationPhase 2 NCT07823322
  8. Notable: PP405 in Adult Females With Androgenetic Alopecia Recruitment opened Pelage Pharmaceuticals, Inc.Phase 2 NCT07907783
  9. Notable: ACE723, A Dual-Payload Antibody Drug Conjugate, · Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs Recruitment opened Acepodia Biotech, Inc.Phase 1 NCT07861425
  10. Notable: Aleniglipron Hepatic Impairment Study Recruitment opened Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsPhase 1 NCT07872033
  11. Notable: Lepodisiran (LY3819469) · High Lipoprotein(a) Recruitment opened Eli Lilly and CompanyPhase 1 NCT07914738
  12. Notable: Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach · Excess Body Weight Recruitment opened Novo Nordisk A/SPhase 1 NCT07845578
  13. Notable: Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart Recruitment opened Gan & Lee Pharmaceuticals.Phase 1 NCT07918898
  14. Notable: CP-PCA07 in Combination With Enzalutamide · Castration-Resistant Prostate Cancer Recruitment opened Hyundai Bioscience Co., Ltd.Phase 1 NCT07683013
  15. Notable: INCB161734 · Hepatic Impairment Recruitment opened Incyte CorporationPhase 1 NCT07853040
  16. Notable: Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Recruitment opened National Cancer Institute (NCI)Phase 2/3 NCT07724457
  17. Notable: Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA) Enrolling by invitation only Serene Sleep, Inc.Not applicable NCT07613281
  18. Notable: Registry of Exposure to Gepotidacin (PREG) Recruitment opened GlaxoSmithKlineNot specified NCT07850141
  19. Notable: Robotic Minimally Invasive Benign Hysterectomy Post-Market Clinical Study With the DEXTER Robotic System Recruitment opened Distalmotion SANot specified NCT07746531
  20. Notable: Octane Aether for Treating Chronic Low Back Pain Recruitment opened Octane Innovation Inc.Not applicable NCT07614568
  21. Notable: (Called Marstacimab) · Hemophilia A or B Recruitment opened PfizerNot specified NCT07859527
  22. Notable: Behavioral and/or Mirabegron · Urinary Symptoms in Parkinson Disease Recruitment opened VA Office of Research and DevelopmentPhase 4 NCT07187466
  23. Notable: Oral TLR8 Agonist Selgantolimod on HBsAg · Both Chronic Hepatitis B and HIV Reclassified as terminated (was completed) National Institute of Allergy and Infectious Diseases (NIAID)Phase 2 NCT05551273
  24. Notable: Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Recruitment opened AIDS Malignancy ConsortiumPhase 2 NCT07662928
  25. Notable: Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy · Newly Diagnosed Glioblastoma, SAGA 2.0 Trial Recruitment opened Mayo ClinicPhase 3 NCT07935889